GlobalBlock Digital

On April 6, 2026, GlobalBlock Digital Asset Trading released results for the quarter ended December 31, 2025, and reported a loss of CAD 0.040 per share. In the same quarter a year earlier the loss was CAD 0.020 per share. No further operational details were provided. » More on finanzen.net

Telomir Pharmaceuticals sold 1,550,000 common shares to institutional investors via an at-the-market program at an average price of $1.87 per share, generating gross proceeds of about $2.9 million before fees. The transaction closed on August 28 and was executed through Rodman & Renshaw on the StockBlock platform; the placement was at a premium to the prior day's closing price and did not include warrants. The information comes from an SEC filing, and Telomir is classified as an Emerging Growth Company. » More on de.investing.com

MIRA Pharmaceuticals released preclinical data showing that the oral drug candidate Ketamir-2 outperformed ketamine, pregabalin and gabapentin in animal models at restoring sensory function and reversing pain behaviors. The company reports a planned Phase 1 study in Israel with no safety concerns, an FDA IND clearance for Ketamir-2, and intends to file a Phase 2a protocol in Q4 2025; it also reported positive preclinical results for a topical Ketamir-2 cream and another candidate, SKNY-1. In parallel, MIRA raised about $2 million through an at-the-market placement, executed by Rodman & Renshaw via the StockBlock platform. » More on de.investing.com